Charles Schwab’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-838,078
| Closed | -$5.05M | – | 3269 |
|
|
2019
Q4 | $5.05M | Buy |
838,078
+3,881
| +0.5% | +$22.5K | ﹤0.01% | 2007 |
|
|
2019
Q3 | $3M | Buy |
834,197
+38,958
| +5% | +$150K | ﹤0.01% | 2231 |
|
|
2019
Q2 | $2.13M | Buy |
795,239
+20,215
| +3% | +$59.7K | ﹤0.01% | 2351 |
|
|
2019
Q1 | $2.29M | Buy |
775,024
+37,171
| +5% | +$91.3K | ﹤0.01% | 2320 |
|
|
2018
Q4 | $1.17M | Sell |
737,853
-18,778
| -2% | -$53.1K | ﹤0.01% | 2496 |
|
|
2018
Q3 | $2.79M | Buy |
756,631
+98,287
| +15% | +$293K | ﹤0.01% | 2320 |
|
|
2018
Q2 | $1.86M | Sell |
658,344
-42,504
| -6% | -$145K | ﹤0.01% | 2404 |
|
|
2018
Q1 | $2.6M | Buy |
700,848
+151,659
| +28% | +$496K | ﹤0.01% | 2228 |
|
|
2017
Q4 | $1.58M | Buy |
549,189
+23,577
| +4% | +$85.7K | ﹤0.01% | 2383 |
|
|
2017
Q3 | $2.36M | Buy |
525,612
+68,271
| +15% | +$303K | ﹤0.01% | 2230 |
|
|
2017
Q2 | $2.1M | Buy |
457,341
+2,850
| +0.6% | +$11.5K | ﹤0.01% | 2205 |
|
|
2017
Q1 | $1.91M | Buy |
454,491
+25,650
| +6% | +$107K | ﹤0.01% | 2216 |
|
|
2016
Q4 | $1.77M | Sell |
428,841
-12,019
| -3% | -$63.9K | ﹤0.01% | 2227 |
|
|
2016
Q3 | $3.57M | Buy |
440,860
+21,490
| +5% | +$183K | ﹤0.01% | 1850 |
|
|
2016
Q2 | $3.27M | Buy |
419,370
+28,264
| +7% | +$242K | ﹤0.01% | 1824 |
|
|
2016
Q1 | $3.02M | Buy |
391,106
+8,011
| +2% | +$58.7K | ﹤0.01% | 1827 |
|
|
2015
Q4 | $4.13M | Buy |
383,095
+25,002
| +7% | +$227K | 0.01% | 1650 |
|
|
2015
Q3 | $2.48M | Buy |
358,093
+22,162
| +7% | +$181K | ﹤0.01% | 1946 |
|
|
2015
Q2 | $2.98M | Buy |
335,931
+10,011
| +3% | +$94.7K | ﹤0.01% | 1874 |
|
|
2015
Q1 | $3.21M | Buy |
325,920
+59,817
| +22% | +$747K | ﹤0.01% | 1787 |
|
|
2014
Q4 | $3.26M | Buy |
266,103
+4,142
| +2% | +$50.6K | ﹤0.01% | 1725 |
|
|
2014
Q3 | $2.62M | Buy |
261,961
+28,075
| +12% | +$261K | ﹤0.01% | 1809 |
|
|
2014
Q2 | $1.77M | Buy |
233,886
+18,200
| +8% | +$72.6K | ﹤0.01% | 2040 |
|
|
2014
Q1 | $710K | Buy |
215,686
+6,000
| +3% | +$21K | ﹤0.01% | 2447 |
|
|
2013
Q4 | $697K | Sell |
209,686
-1,059
| -0.5% | -$3.07K | ﹤0.01% | 2445 |
|
|
2013
Q3 | $559K | Buy |
210,745
+21,649
| +11% | +$148K | ﹤0.01% | 2506 |
|
|
2013
Q2 | $1.58M | Buy |
+189,096
| New | +$1.44M | ﹤0.01% | 1904 |
|
Charles Schwab's ACHN Position: Q1 2020 in Review
Charles Schwab sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 838,078 shares — an estimated $5.05M sold.
Charles Schwab first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $5.05M in Q4 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Charles Schwab reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Charles Schwab sold 838,078 Achillion Pharmaceuticals shares in Q1 2020, an estimated $5.05M.
- Charles Schwab first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Charles Schwab's Achillion Pharmaceuticals position peaked at $5.05M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Charles Schwab's 13F filing for Q1 2020, filed 15 May 2020.